Health-tech startup Dectrocel raises Rs 4 Cr from IAN Group-backed BoiAngels
In a funding round led by IAN Group-powered BioAngels, with participation from PadUp Ventures and Vinners, Dectrocel, a health-tech startup creating AI-powered diagnostic solutions, has raised Rs 4 crore. In this round, Nitin Zamre, Samir Kalia, and Mitesh Shah are important IAN investors.
The money will be used to expand into foreign markets, improve self-learning foundational multimodal AI technology, scale its commercial operations throughout India, and expedite the launch of its upcoming AI Tools in CT/MRI/PET-CT and HPB diagnostic modules, Dectrocel stated in a press release.
Dectrocel, a health-tech company co-founded in 2020 by Ankit Shukla, Saumya Shukla, and Nikhil Mishra, is creating AI-powered diagnostic tools for hepato-pancreatico-biliary (HPB) and respiratory disorders. Its flagship product, DecXpert, provides chest X-ray and CT scan interpretations and is one of only three AI-based diagnostic tools authorized for clinical use in India by CDSCO. It claims to be 10 times faster and 98% accurate.
The Lucknow-based company claims that DecXpert fills the critical diagnostic gap brought on by India’s severe radiology shortage (1:125,000 ratio), especially in tier-2 and smaller cities where error rates of 25–40% and diagnosis delays of 7–10 days are typical.
“We’re not just building AI diagnostic tools – we’re saving lives by ensuring that a patient in a tier-3 city gets the same quality chest X-ray/ CT /MRI/PET-CT Scan interpretation as someone in a metro hospital. Our 40.1% improvement in missed case detection, validated in Nature Scientific, proves that AI can be the great equalizer in healthcare access,” Ankit Shukla, founder & technical director, Dectrocel.
Dectrocel intends to penetrate the Rs 1,000 crore digital X-ray market in India, introduce DecXpert commercially across OEM partner networks, and start out in Southeast Asia. With new diagnostic modules for CT/MRI/PET-CT scans and HPB disease modules, the company is also working on product diversification. Additionally, it is improving AI capabilities for self-learning adaptability and broader pathology detection.
